Visits to oncologists up, but profit per patient is on the decline
October 2nd 2008SAN FRANCISCO-New patient visits to oncologists increased by 22% over the past 3 years; however, oncologists’ average profit per patient fell by 91%. These were among the key findings of Onmark’s 2008 “Office-Based Oncology Benchmarking Survey,” which measures m operational and financial benchmarks among community-based oncology practices.
NIH bankrolls molecular probes for targeted therapy
October 1st 2008The National Institutes of Health (NIH) will devote $70 million to accelerate the development of small molecule probes at 9 US centers, including the Burnham Center for Chemical Genomics in La Jolla, California (John Reed, MD, PhD, principal investigator); Johns Hopkins Ion Channel Center in Baltimore (Min Li, PhD); and the University of Kansas Specialized Chemistry Center in Lawrence (Jeffrey Aube, PhD).
Oropharyngeal ca: IMRT spares salivary glands
October 1st 2008BOSTON-A multicenter trial that tested intensity-modulated radiation therapy for patients with early-stage oropharyngeal cancer showed a reduction in long-term salivary toxicity while achieving good tumor control, according to research presented at ASTRO 2008.
Oncology electronic health records: More than just an e-secretary
October 1st 2008Electronic health records can help oncology practices save money and work smarter. Then why has the adoption of e-technology been so frustratingly slow? A recent survey in the New England Journal of Medicine found that only 4% of physicians reported having a fully functional electronic health record (EHR) system; only 13% reported having a basic system (NEJM 359: 50-60, 2008).
Addressing Psychological Challenges After Cancer: A Guide for Clinical Practice
October 1st 2008The person diagnosed with cancer typically is confronted with a variety of difficult challenges. Treatment for cancer can be physically arduous, it generally disrupts patients’ social and work life, and it may even limit their ability to care for themselves or live independently for some period of time. In addition to these physical and functional burdens, cancer patients often face fears of death or disability, and may be prone to feelings of isolation or depression.
Post-Trauma Symptoms in Cancer Survivors
October 1st 2008Diagnosis and treatment of cancer are potential traumatic stressors.[1,2] Others may include but are not limited to interpersonal violence, military combat, natural and man-made disasters, and displacement.[2] In response to the intense fear, helplessness, terror, and uncertainty that traumatic stressors can provoke, post-trauma symptoms (PTS) classically develop in three clusters: re-experiencing, avoidance/numbing, and hyperarousal.[2]
Barrie Cassileth, an integrative medicine pioneer
October 1st 2008When you remodel an old bank building, you may wind up with your office in a vault, as did two staff members at the Bendheim Integrative Medicine Center, Memorial Sloan-Kettering Cancer Center’s outpatient facility for complementary services and therapies.
Move to make CME an out-of-pocket cost gains ground
October 1st 2008STANFORD, California-In a bid to become free of commercial influence, Stanford University School of Medicine has cut off funding from pharmaceutical and medical device companies for some continuing medical education (CME) programs. As of last month, educational offerings will be held at Stanford facilities rather than resorts and hotels, whenever possible.
Is concurrent chemotherapy/IMRT too toxic and dangerous for use in H&N cancer?
October 1st 2008SAN FRANCISCO-In a recent debate, both speakers agreed that IMRT with concurrent chemotherapy is toxic in patients with head and neck cancer, but disagreed on whether the risk/benefit ratio justifies its use. The event was held at the 2008 International Conference on Head and Neck Cancer, sponsored by the American Head & Neck Society.
Older multiple myeloma patients show active response to novel agents
October 1st 2008Fully 88% of older adults with newly diagnosed multiple myeloma have at least a very good partial response when treated with low-dose autologous stem cell transplantation that is preceded by bortezomib-containing induction therapy and followed by lenalidomide-containing consolidation and maintenance therapy, according to trial results from the University of Turin in Italy.
Calcium-magnesium is neuroprotective in patients receiving oxaliplatin
October 1st 2008The combination of intravenous calcium and magnesium salts (CaMg) is associated with a nearly one-half reduction in the rate of chronic oxaliplatin (Eloxatin)-induced sensory neurotoxicity among patients receiving adjuvant FOLFOX therapy for colon cancer, compared with placebo.
Revamped quality assurance approach embarks on a new era in clinical trials
October 1st 2008BOSTON-It’s no secret that quality assurance is essential for ensuring the accuracy of clinical trials. But the potential for real-time intervention also gives modern-era QA an unprecedented ability to improve outcomes, according to research presented at the ASTRO 2008 meeting (abstract 2576).
Panel pans FDG-PET for new Medicare oncology coverage
September 2nd 2008A Centers for Medicare and Medicaid Services advisory panel has found that most available clinical data for nine conditionally approved cancer indications of FDG-PET, evaluated by the National Oncologic PET Registry (NOPR) and a separate Canadian study, are too ambivalent to support Medicare coverage.
Sen. Kennedy's brain tumor puts spotlight on new treatment
September 2nd 2008News of Sen. Edward Kennedy’s diagnosis with a malignant glioma shocked the nation. It has also raised awareness about the grim prognosis associated with this type of brain tumor. A new study conducted by the American College of Radiology’s Radiation Therapy Oncology Group (RTOG) could bring hope to glioma patients.
Neoadjuvant Chemotherapy for Ovarian Cancer: The Debate Reconsidered
September 2nd 2008The question of a well-defined role for the use of neoadjuvant chemotherapy in the treatment of ovarian cancer is recognized to be one of the most hotly debated issues in the management of female pelvic malignancies.[1-3] One group of oncologists would argue that it should be the rare patient (eg, with severe comorbidity) who is not a candidate for an initial attempt at maximal cytoreduction.[1]
PET brings treatment changes in majority of colon ca cases
September 2nd 2008MELBOURNE, Australia-The largest multi-institutional study to date examining the effect of PET on the management of recurrent colorectal cancer has shown that PET led to change in the treatment plans for more than half of patients.